Indrayani Biotech Allots 83.64 Lakh Rights Shares at ₹15

Indrayani Biotech Limited approved the allotment of 83.64 lakh rights equity shares at an issue price of ₹15 each on November 3, 2026, taking its fully paid equity share count to 5.30 crore shares and adding 8.61 lakh partly paid shares. The allotment completes a key stage of the company's rights issue process.

What did Indrayani Biotech approve in its rights issue allotment?

Indrayani Biotech approved the Basis of Allotment for 83,64,036 rights equity shares through its Rights Issue Committee on November 3, 2026. The committee considered and approved the allotment after the Basis of Allotment was finalised in consultation with BSE Limited, the designated stock exchange.

The rights shares have a face value of ₹10 each and were issued at ₹15 per share, including a premium of ₹5 per share. The allocation comprised 75,03,333 fully paid equity shares and 8,60,703 partly paid equity shares. This distinction is important because the partly paid shares carry only the amount received at the application stage until further calls, if any, are made under the issue terms.

BSE confirmed its approval of the Basis of Allotment through an email dated November 2, 2026. The Rights Issue Committee met from 4:30 pm to 5:30 pm on November 3, and the company disclosed the outcome under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

How were the 83.64 lakh rights shares structured?

The 83.64 lakh allotted shares were split between fully paid and partly paid instruments under the rights issue. Of the total, 75,03,333 shares were fully paid at ₹15 per share, while 8,60,703 shares were partly paid on receipt of application money of ₹3.75 per share.

For the partly paid shares, the ₹3.75 application money included ₹2.50 towards face value and ₹1.25 towards premium. The company stated that these shares had a paid-up value of ₹2.50 per share at allotment. The full issue price of ₹15 consisted of ₹10 face value and a ₹5 securities premium.

The rights issue had been announced with a rights ratio of five shares for every seven shares held, with a record date of April 28, 2026. The issue price and premium were therefore set before the allotment process was completed. The November approval records the final allocation rather than a fresh capital-raising proposal.

How did the allotment change Indrayani Biotech's equity capital?

The allotment increased Indrayani Biotech's fully paid equity share capital from 4,55,36,256 fully paid shares to 5,30,39,589 fully paid shares. In addition, the company now has 8,60,703 partly paid-up equity shares following the rights issue allotment.

Taken together, the post-allotment equity base comprises 5,39,00,292 instruments, including fully paid and partly paid shares. The company also reported that its paid-up equity share capital increased from about ₹45.54 crore to about ₹53.04 crore. These figures reflect the additional equity issued through the completed allotment.

For existing shareholders, the larger equity base is a relevant factor when assessing the company's per-share financial metrics and ownership structure. The rights issue allowed eligible shareholders to apply for additional shares in the stated ratio, while the eventual allotment established the number of shares added to the capital structure.

Why does the rights issue outcome matter to investors?

The rights issue outcome matters because it formally expands Indrayani Biotech's equity base and records the mix of fully paid and partly paid securities that will be outstanding after allotment. Investors assessing the company will need to account for both categories when reviewing the share capital disclosed by the company.

The fully paid allotment of 75.03 lakh shares represents the larger portion of the issuance. The 8.61 lakh partly paid shares have received ₹3.75 per share on application, compared with the ₹15 issue price, and therefore remain distinct from the fully paid shares in the company's capital structure.

No share-price movement, use of proceeds, or timetable for any subsequent calls on the partly paid shares was disclosed in the provided allotment outcome. As a result, the disclosed event is limited to the finalisation of the Basis of Allotment, the number of shares allotted, the payment structure, and the resulting increase in share capital.

What is the timeline for Indrayani Biotech's rights issue?

Indrayani Biotech's rights issue process included a record date in April 2026, followed by BSE's consideration of the Basis of Allotment in November and the committee's final approval a day later. The sequence shows the transition from setting entitlement terms to the formal allotment of rights shares.

The company had earlier fixed April 28, 2026 as the record date for the partly paid rights issue. It subsequently reported the allotment outcome after BSE, acting as the designated stock exchange, approved the Basis of Allotment on November 2, 2026.

Conclusion

Indrayani Biotech has completed the allotment stage for 83.64 lakh rights shares issued at ₹15 each, comprising 75.03 lakh fully paid shares and 8.61 lakh partly paid shares. The transaction increased the company's fully paid equity share count to 5.30 crore and added a separate pool of partly paid equity shares.

Investors can watch for any company disclosures concerning further calls on the 8.61 lakh partly paid shares and updates to the post-issue share capital. The provided allotment outcome does not disclose a future call schedule or the use of proceeds from the rights issue.